Sorry. not the previous post was not that clear.
Hitesh Mistry on X
Hitesh is PYC Senior Consultant.
David Hodson is a employee at PYC as Biosimulation Scientist.
David has been working with Astra Zeneca and others on data to do with DDR (DNA Damage Response)
The paper for this work is here: https://ascpt.onlinelibrary.wiley.com/doi/10.1002/psp4.13026
We know that PYC and Merck Group are collaborating on DDR to.
No official news regarding PYC and AZ working together. Is David writing papers in his spare time?
Hitesh also reposted this: https://twitter.com/PavlosMsaouel/status/1704272884754006506?s=20
https://aacrjournals.org/clincancerres/article-abstract/doi/10.1158/1078-0432.CCR-23-2222/729130/Novel-clinical-trial-designs-with-dose?redirectedFrom=fulltext
The post itself mentions #ProjectOptimus, but the abstract doe not. I dont have full access to the paper, so can not see the conclusion.
#DavidHodson had more fun with the AstraZeneca IO/RT/DDR data with
@JimboYates Notice the name AstraZeneca!
and others from UoM and AZ "Mixed effects modeling of radiotherapy in combination with immune checkpoint blockade or inhibitors of the DNA damage response pathway" Also linked to this: https://ascpt.onlinelibrary.wiley.com/doi/10.1002/psp4.13026
David Hodson works at PYC as a Bio simulation Scientist.
Also, he retweeted this: https://x.com/PavlosMsaouel/status/1704272884754006506?s=20
Mentions Project Optimus.
Yesterday. Bicycle Therapeutics put out a tweet saying " It’s an honor to be awarded Quoted Company of the Year by @businessweekly
! Thank you for recognizing our efforts to develop potentially life-changing medicines for patients around the world."
https://twitter.com/Bicycle_tx/status/1703787566812573706?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Etweet
Good for them.
Sienna found it by scanning thru the clinical trials website
Hit n miss I know
I wonder if this is the company which recently gave PYC a £125k deal?
NuCana PLC, based in UK.
https://www.nucana.com/pipeline.html
https://clinicaltrials.gov/study/NCT05714553?locStr=UK&country=United%20Kingdom&distance=50&aggFilters=phase:0%201&limit=100&page=1&rank=52
time lines appear to fit? NU3373 also appears to be their lead asset as mentioned in the RNS??
Thoughts.
According to Linkedin, he still works for PYC.
He was "Head of digital performance" (Consultant), then after leaving to go to Pfizer, he came back and is now "digital performance director" (Consultant)
Hiya, according to Linkedin, Ken was the Head of Digital Performance (consultant) from Nov 2018 - Oct 2019 · 1 yr
& is now
Digital Performance Director (consultant)Digital Performance Director (consultant)
Jan 2022 - Present · 1 yr 9 mos
He was with Pfizer UK Digital Lead (Oncology)Pfizer UK Digital Lead (Oncology)
Oct 2019 - Dec 2021 · 2 yrs 3 mos
He has recently posted this:
I’m happy to share that I’ve obtained a new certification: Machine Learning in the Enterprise from Google!
Was apparently NT for the last 45mins of the trading day
Edit...maye = mate.
Impressive reversal yesterday? Going from approx 13% down to near flat.
Odinviking thank you for your reading of the book. Did you see it switch? To me it seemed it was taken down on sells (yes) but the sells did not warrant the drop??
I guess the 300k delayed buy by SFU maye helped also?
MS, you have said 2.3 seems a tough nut to crack and hold, certainly seems that way.
Thank you Mr P for your reply.
I do not have the luxury of having L2.
Maybe a P&D has gone incognito now, as before, you could see it, esp on X with rockets, and flash cars emojis everywhere, now there is nothing.
You are right thou, a TR1 from a new II etc would show great confidence.
I sincerely hope you and S4 are wrong on this potential placing.
From now on, i will just post things on the way i see them, any relevant info ( the way i see it ) etc.
I am not going to get involved in any personal or quasi negativity.
They are UK L, but i am shocked you did not know that.
Yes, a nice day.
Porky, i know you are more versed in all thinks stockmarket than me, but where is the evidence of a P&D?
Unless that scenario has changed over the last few years, i see no ramping on X, there is only a few commenting on it (namely moi), there has only been 36 posts here all day, and no sign of Ria and their every minute commentary. There is next to nothing on Telegram.
Where is the evidence?
Today, Cellcentric, who we did a collaboration on CCS1477 ( Inobrodib ) with, announced a $3M cash injection from BrightEdge who are affiliated with AmericanCancer.
This is on top of the $25m from Pfizer some weeks ago.
L, the 2 year contract (project) is for Numab.
L who knows?
This new trial for BT8009 is due to start in Jan 2024, and its specifically ( from what i understand ) for Expediting development of BT8009 for metastatic bladder cancer.
The whole presentation is here: https://investors.bicycletherapeutics.com/static-files/265210c3-233f-4dd8-af32-d34592398d85
Interesting graphic shows Broad range of programs supports robust nature of
Bicycle® platform. Shows both internal programs and external programs, and who these partners are.
Today PYC updated their website to show the new COO and Dr Christophe Chassagnole has gone to CSO.
https://www.physiomics.co.uk/about/team/
Bicycle therapeutics put a tweet and press release today.
https://investors.bicycletherapeutics.com/news-releases/news-release-details/bicycle-therapeutics-announces-expedited-development-plan-bt8009
They are aligning with FDA to hopefully expedite the development of BT8009.
We have a very good working relationship with Bicycle. We have worked / are working on BT8009
This trial is due to start in 2024, i would be hoping to get news from PYC that they again have been chosen with Bicycle in early 2024.
Life, do you know of a Dr Zahid Ali of Kings college, he is a visiting fellow, and also works for UCB. He used to be a TR1 significant holder, but not on list now due to dilution after the raise a few months ago?
I cant work out the trade either?
Price sold was 1.835p , at the time at 1357 on 07.09.23 the sp was 1.80 to 2.00, looking at that, you'd have to say it was more a sell than a buy? But who knows? Welcome btw life.